Chinese Japanese Germany Korea


Description References
Flutamide structure
Chemical Name:
Molecular Formula:
Formula Weight:
MOL File:

Flutamide Properties

Melting point:
112 °C
Boiling point:
400.3±45.0 °C(Predicted)
1.3649 (estimate)
storage temp. 
Practically insoluble in water, freely soluble in acetone and in ethanol (96 per cent).
CAS DataBase Reference
13311-84-7(CAS DataBase Reference)
NCI Dictionary of Cancer Terms
NCI Drug Dictionary
ATC code
Proposition 65 List
EPA Substance Registry System
Flutamide (13311-84-7)
  • Risk and Safety Statements
Signal word  Warning
Hazard statements  H302+H312+H332-H361-H302-H312-H332
Precautionary statements  P261-P280-P301+P312+P330
Hazard Codes  Xn,Xi
Risk Statements  20/21/22-63-36/37/38
Safety Statements  22-36-36/37/39-27-26
WGK Germany  3
RTECS  UG5700000
HS Code  29242990

Flutamide price More Price(14)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Sigma-Aldrich Y0001591 Flutamide for system suitability European Pharmacopoeia (EP) Reference Standard 13311-84-7 $190 2021-03-22 Buy
Sigma-Aldrich F0285600 Flutamide European Pharmacopoeia (EP) Reference Standard 13311-84-7 $190 2021-03-22 Buy
Sigma-Aldrich 94495 Flutamide certified reference material, TraceCERT 13311-84-7 50mg $196 2021-03-22 Buy
Sigma-Aldrich 1285851 Flutamide United States Pharmacopeia (USP) Reference Standard 13311-84-7 200mg $366 2021-03-22 Buy
TCI Chemical F0663 Flutamide >98.0%(GC) 13311-84-7 5g $45 2021-03-22 Buy

Flutamide Chemical Properties,Uses,Production


Flutamide is a kind of synthetic, non-steroidal antiandrogen which is mainly used for the treatment of prostate cancer. It is a kind of toluidine derivative and a nonsteroidal antiandrogen with a similar structure of bicalutamide and nilutamide. The mechanism of its anti-cancer property is through acting as a selective antagonist of the androgen receptor (AR), preventing androgens such as testosterone and its active metabolite dihydrotestosterone from binding to ARs in the prostate gland. This process inhibits androgen-dependent DNA and protein synthesis in the tumor cell. Therefore, it can prevent androgens from stimulating the growth of prostate cancer cells. Moreover, it can also be used for the treatment of hyperandrogenism in women. It is quite effective in alleviating symptoms such as acne, seborrhea, hirsutism and androgenetic alopecia. Finally, it is also useful as a component in the transgender hormone therapy.



Flutamide is an orally active, non-steroidal antiandrogen indicated for the treatment of prostatic cancer in both castrates and noncastrates.

Chemical Properties

Light Yellow Solid


scheting (USA)


Flutamide was first described as a member of a series of N-acyl anilides synthesized at Monsanto in the 1960s during a compound finding program aiming at bacteriostatic agents. Soon after, at Schering Corp., the compound was characterized pharmacologically and further developed as SCH-13521. It was found that flutamide inhibits agonist action at the AR by replacing the agonist at the ligand binding site, being the first nonsteroidal compound possessing anti-androgenic activity in animals. In contrast to steroidal anti-androgens, for instance, cyproterone acetate, which also displays significant progestational activity, flutamide has no other hormonal activity. There is also no reduction of serum testosterone levels seen with flutamide but rather a slight increase in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) resulting in elevated serum testosterone levels. This accounts for the beneficial maintenance of libido and potency in sexually active patients. On the other hand, elevated serum estradiol levels resulting from peripheral testosterone aromatization leading to gynecomastia were observed in patients.


Antiandrogen; antineoplastic (hormonal).




Flutamide is a nonsteroidal antiandrogen drug; antineoplastic (hormonal).


Besides prostate cancer, flutamide has also been tested and/or used off-label in other hyperandrogenism-related disorders like benign prostatic hyperplasia, acne vulgaris, and hirsutism syndrome. Due to its teratogenic potential, flutamide is restricted for premenopausal women and used only in combination with effective contraception.


Flutamide is a prodrug possessing only weak androgen antagonistic activity of its own. It is oxidized in vivo to the active principle hydroxyflutamide (6) as primary metabolite.The elimination half-life of hydroxyflutamide is relatively short, 4–6.6 h in patients after a single oral 250 mg dose of flutamide. Therefore, oral dosing of 250 mg flutamide three times daily was applied clinically. The first introduction into clinical studies was achieved in 1975 as single agent in the first-line treatment of advanced prostate carcinoma. In the United States, flutamide was finally approved by FDA in 1989 for the treatment of metastatic prostate cancer in combination with a luteinizing hormone-releasing hormone (LHRH, also referred to as gonadotropin-releasing hormone (GnRH)) agonist, for instance, leuprorelin acetate (Leuprolide(R), Lupron(R)) or goserelin acetate (Zoladex(R)).The combined androgen blockade by flutamide plus an LHRH agonist or surgical castration was introduced in order to maximize the effects of androgen ablation. Flutamide also inhibits the secretion of androgens from the adrenal gland, which is not impaired by chemical castration with LHRH agonists or by surgical castration. In addition, the AR antagonist avoids the unacceptable initial tumor flare that occurs when LHRH agonists are given alone.
Favorable response to flutamide was seen with advanced prostate carcinoma patients after single-agent treatment as well as after combination treatment. The progression of the disease was slowed and the lifetime of patients was extended. For instance, the National Cancer Institute (NCI) initiated a trial (INT-0036) and concluded that the combination of leuprolide with flutamide was more effective than leuprolide alone in patients with advanced prostate cancer. However, significant side effects were also reported.The most frequently observed adverse events are summarized in Table 1. Flutamide evidently amplifies some of the LHRH agonist-induced side effects.

Table 1 Side effects of LHRH antagonist alone and in combination with flutamide.


Flutamide (Eulexin) is a nonsteroidal androgen receptor antagonist that inhibits androgen binding to its nuclear receptor. It is effective in inducing prostatic regression and is approved for the treatment of prostatic carcinoma. For maximum clinical effectiveness it has to be used in combination with a GnRH antagonist (e.g., leuprolide acetate) that inhibits androgen production. Flutamide may eventually be used for the treatment of hirsutism and male pattern baldness in women if a topical preparation is developed.


Flutamide (Eulexin) is a nonsteroidal antiandrogen compound that competes with testosterone for binding to androgen receptors. The drug is well absorbed on oral administration. It is an active agent in the hormonal therapy of cancer of the prostate and has been shown to complement the pharmacological castration produced by the gonadotropin-releasing hormone (GnRH) agonist leuprolide. Flutamide prevents the stimulation of tumor growth that may occur as a result of the transient increase in testosterone secretion after the initiation of leuprolide therapy. The most common side effects of flutamide are those expected with androgen blockade: hot flashes, loss of libido, and impotence. Mild nausea and diarrhea occur in about 10% of patients.

Manufacturing Process

To a stirred, cooled solution of 100 g of 4-nitro-3-trifluoromethylaniline in 400 ml of pyridine, slowly and in a dropwise fashion, add 54 g of isobutyrylchloride and then heat the reaction mixture on a steam bath for 1.5 hours. Cool and pour the resulting mixture into ice water, filter and waterwash the crude anilide and crystallize the product of this example from benzene to obtain analytically pure material, MP 111.5°C to 112.5°C.

brand name

Eulexin (Schering);DROGENIL.

Therapeutic Function


General Description

Flutamide, 2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide, is dosed 3 times daily(250-mg dose; 750-mg total daily dose). A major metaboliteof flutamide, hydroxyflutamide, is a more potent AR antagonistthan the parent compound. This metabolite, which ispresent at a much higher steady-state concentration than isflutamide, contributes a significant amount of the antiandrogen action of this drug. A limiting factor in the useof flutamide is hepatotoxicity in from 1% to 5% of patients.Although the hepatotoxicity usually is reversible followingcessation of treatment, rare cases of death associated withhepatic failure have been reported to be associated with flutamidetherapy. Diarrhea is also a limiting side effect withflutamide therapy for some patients.

Contact allergens

Flutamide is an antiandrogenic hormonal antineoplas tic drug that can induce photosensitivity and porphy ria-like eruption.

Mechanism of action

Flutamide is a nonsteroid drug that possesses antiandrogenic action. It blocks androgens from binding with target tissues, thus preventing androgen action. The mechanism of action is possibly also linked with a halt in dihydrotestosterone transport. It facilitates a reduction in size and density of the prostate gland, and it reduces the amount of metastases in such cancer, for which it is used in palliative treatment of prostate gland cancer.

Clinical Use

Flutamide is a pure antagonist, whereas 2-hydroxyflutamide is a more potent AR antagonist but also can activate the androgenic receptor at higher concentrations. These findings raise the possibility that increased conversion of flutamide to 2-hydroxyflutamide or accumulation of 2-hydroxyflutamide in cells may contribute to the anomalous responses to flutamide that are observed in some advanced prostate cancers.

Chemical Synthesis

Flutamide, 4-nitro-3-trifluoromethylisobutyranilide (29.2.15), a nonsteroid antagonist of androgens, is made by acylating 4-nitro-3-trifluoromethylaniline with isobutyric acid chloride.

Flutamide Preparation Products And Raw materials

Raw materials

Preparation Products

Flutamide Suppliers

Global( 330)Suppliers
Supplier Tel Fax Email Country ProdList Advantage
Capot Chemical Co.,Ltd.
+86(0)13336195806 +86-571-85586718
+86-571-85864795 China 20012 60
Henan DaKen Chemical CO.,LTD.
+86-371-66670886 China 20898 58
Henan Tianfu Chemical Co.,Ltd.
0371-55170693 CHINA 22607 55
Guangzhou PI PI Biotech Inc
020-81716319; China 3245 55
Hubei XinRunde Chemical Co., Ltd.
02783214688 CHINA 567 55
Nanjing Finetech Chemical Co., Ltd.
025-85710122 17714198479
025-85710122 CHINA 890 55
career henan chemical co
+86-371-86658258 CHINA 29954 58
+86 18953170293
+86 0531-67809011 CHINA 2941 58
Hebei Jimi Trading Co., Ltd.
+86 319 5273535 CHINA 292 58
Cangzhou Wanyou New Material Technology Co.,Ltd
18631714998 CHINA 914 58

View Lastest Price from Flutamide manufacturers

Image Release date Product Price Min. Order Purity Supply Ability Manufacturer
2021-11-09 Flutamide
US $0.00 / Kg/Bag 2Kg/Bag USP 20 tons Sinoway Industrial co., ltd.
2021-11-08 Flutamide
US $10.00 / KG 1KG 99.9% 100MT/Month Wuhan wingroup Pharmaceutical Co., Ltd
2021-10-20 Flutamide
US $350.00 / KG 1KG 99% 9000kg/per week Hebei Lingding Biological Technology Co., Ltd

Flutamide Spectrum

13311-84-7(Flutamide)Related Search:

Copyright 2017 © ChemicalBook. All rights reserved